Nuvalent, Inc. (NUVL) Stock Price & Analysis
Nuvalent, Inc. (NUVL) rose 39.28% to USD 123.25 as of June 9, 2026 at 23:42 UTC, according to Nexqual real-time market data.
NUVL last closed at USD 88.49; the session ranged USD 122.81–123.62 on volume of 51,678,614 shares. Market capitalization is $9.75B, with a 52-week range of USD 71.13–123.62 (NMS). Source: Nexqual, June 9, 2026 at 23:42 UTC.
Key Statistics (as of June 9, 2026 at 23:42 UTC)
| Price | USD 123.25 |
|---|---|
| Change | ▲ 39.28% (up) |
| Previous Close | USD 88.49 |
| Open | USD 122.81 |
| Day Range | USD 122.81 – 123.62 |
| 52-Week Range | USD 71.13 – 123.62 |
| Volume | 51,678,614 shares |
| Market Cap | $9.75B |
| Exchange | NMS |
Technical Analysis (NUVL)
Nexqual's technical model rates NUVL "NEUTRAL" based on 4 bullish and 3 bearish signals across 124 daily candles, as of June 9, 2026 at 23:42 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 65.77 (neutral) |
| vs SMA50 | Above (USD 102.79) |
| MACD | -0.71 (negative) |
Analyst Ratings (NUVL)
Wall Street analysts rate NUVL "Strong Buy" based on 19 analysts, with a mean price target of USD 143.62 (range USD 116–172), per Nexqual as of June 9, 2026 at 23:42 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 19 |
| Mean Target | USD 143.62 |
| High Target | USD 172 |
| Low Target | USD 116 |
| Buy / Hold / Sell | 20 / 0 / 0 |
Earnings (NUVL)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -1.38 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.39 vs est -1.31 ▼ miss |
| 2025-12-31 | USD -1.58 vs est -1.44 ▼ miss |
| 2025-09-30 | USD -1.7 vs est -1.32 ▼ miss |
| 2025-06-30 | USD -1.39 vs est -1.15 ▼ miss |
Source: Nexqual, June 9, 2026 at 23:42 UTC.
Financials & Fundamentals (NUVL)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -41.19% |
| Current Ratio | 16.14 |
| Total Cash | $1.29B |
| Total Debt | $0 |
| Free Cash Flow | $-180.43M |
Source: Nexqual, June 9, 2026 at 23:42 UTC.
Financial Health Score (NUVL)
Nexqual rates Nuvalent, Inc.'s overall financial health "Weak" across five dimensions, as of June 9, 2026 at 23:42 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $1.29B cash, no debt |
| Cash Flow | Weak — Operating cash flow -$313M |
| Efficiency | Critical — ROE -41%, ROA -22.5% |
Ownership (NUVL)
| Insider Ownership | +2.76% |
|---|---|
| Institutional Ownership | +113.27% |
| Shares Outstanding | 73.69M |
| Float | 49.00M |
| Short % of Float | +10.44% |
Source: Nexqual, June 9, 2026 at 23:42 UTC.
Leadership (NUVL)
Nuvalent, Inc. is led by James R. Porter (age 49), CEO, President & Director, per Nexqual as of June 9, 2026 at 23:42 UTC.
| CEO, President & Director | James R. Porter (age 49) |
|---|---|
| CFO & Treasurer | Alexandra Balcom (age 41) |
| Chief Scientific Officer | Henry Pelish (age 52) |
| Senior Director of Investor Relations & Corporate Communications | Chelcie Lister |
| Senior Vice President of Translational Development | John Soglia |
Major Backers & Investors (NUVL)
Notable institutional backers of Nuvalent, Inc. include Deerfield Management Company, L.P, FMR, LLC, Paradigm Biocapital Advisors LP, according to Nexqual as of June 9, 2026 at 23:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Deerfield Management Company, L.P | 23.45% |
| FMR, LLC | 12.61% |
| Paradigm Biocapital Advisors LP | 7.24% |
| JPMorgan | 4.2% |
| RA Capital Management, L.P. | 3.44% |
| Wellington Management | 3.36% |
| Fidelity | 3.23% |
| Price (T.Rowe) Associates Inc | 2.8% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 13.32% |
| BlackRock | 8.16% |
Source: Nexqual, June 9, 2026 at 23:42 UTC.
From Nuvalent, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- We also rely on trade secrets and know-how relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen and maintain our proprietary position in the field of oncology.
- While we believe that our technology, the expertise of our team, and our development experience and scientific knowledge provide us with competitive advantages, we face competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions.
- Any owned or in-licensed patent rights we may obtain may not enable us to prevent others from replicating, manufacturing, using, or administering our product candidates for any indication.
- We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment, and personnel while also enabling us to focus our expertise and resources on the development and commercialization, if approved, of our product candidates.
Partnerships
- Revenue Sharing Agreement with our scientific founder We are party to an Amended and Restated Revenue Sharing Agreement with our scientific founder, Matthew Shair, Ph.D., pursuant to which we were obligated to pay Dr.
- We prioritize therapeutic targets where patient needs and limitations of existing therapies can be identified and characterized in partnership with physician-scientists.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PCVX | Vaxcyte, Inc. | USD 46.88 | ▼ 1.01% |
| IDYA | IDEAYA Biosciences, Inc. | USD 28.07 | ▼ 0.78% |
| EWTX | Edgewise Therapeutics, Inc. | USD 34.06 | ▼ 4.3% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
| KYMR | Kymera Therapeutics, Inc. | USD 76.91 | ▲ 3.75% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:42 UTC. This page is informational and not investment advice.